The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Spice drugs are more than harmless herbal blends: A review of the pharmacology and toxicology of synthetic cannabinoids
Open accessAbstract
“K2” and “Spice” drugs (collectively hereafter referred to as Spice) represent a relatively new class of designer drugs that have recently emerged as popular alternatives to marijuana, otherwise characterized as “legal highs”. These drugs are readily available on the Internet and sold in many head shops and convenience stores under the disguise of innocuous products like herbal blends, incense, or air fresheners. Although package labels indicate “not for human consumption”, the number of intoxicated people presenting to emergency departments is dramatically increasing. The lack of validated and standardized human testing procedures and an endless supply of potential drugs of abuse are primary reasons why researchers find it difficult to fully characterize clinical consequences associated with Spice. While the exact chemical composition and toxicology of Spice remains to be determined, there is mounting evidence identifying several synthetic cannabinoids as causative agents responsible for psychoactive and adverse physical effects. This review provides updates of the legal status of common synthetic cannabinoids detected in Spice and analytical procedures used to test Spice products and human specimens collected under a variety of clinical circumstances. The pharmacological and toxicological consequences of synthetic cannabinoid abuse are also reviewed to provide a future perspective on potential short- and long-term implications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Contributions of the Amygdala to Emotion Processing: From Animal Models to Human Behavior
Phelps, E. A., & LeDoux, J. E. (2005) · Neuron · doi:10.1016/j.neuron.2005.09.025 · Cited by 3,203 · cited 1×
“The hippocampus and the amygdala are brain regions involved, respectively, in memory and the pathophysiology of schizophrenia (Tamminga et al., 2010) and emotion processing (Phelps and LeDoux, 2005).”
BackgroundPertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Di Marzo, V., Elphick, M. R., Greasley, P. J., Hansen, H. S., Kunos, G., Mackie, K., et al. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003004 · Cited by 1,605
Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.
Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., & Moffitt, T. E. (2002) · BMJ · doi:10.1136/bmj.325.7374.1212 · Cited by 1,399
The effects of cannabinoids on the brain
Ameri, A. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00087-2 · Cited by 812
‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs?
Auwärter, V., Dresen, S., Weinmann, W., Müller, M., Pütz, M., & Ferreirós, N. (2009) · Journal of Mass Spectrometry · doi:10.1002/jms.1558 · Cited by 660
Abnormal gray and white matter volume in delusional infestation
Wolf, R. C., Huber, M., Depping, M. S., Thomann, P. A., Karner, M., Lepping, P., & Freudenmann, R. W. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.06.004 · Cited by 606
The Hippocampal Formation in Schizophrenia
Tamminga, C. A., Stan, A. D., & Wagner, A. D. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09081187 · Cited by 582
Discovery of the Presence and Functional Expression of Cannabinoid CB2 Receptors in Brain
ONAIVI, E. S., ISHIGURO, H., GONG, J., PATEL, S., PERCHUK, A., MEOZZI, P. A., MYERS, L., MORA, Z., TAGLIAFERRO, P., GARDNER, E., et al. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1369.052 · Cited by 543
CANNABINOID RECEPTORS AS THERAPEUTIC TARGETS
Mackie, K. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141254 · Cited by 505
Cited by
Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations
Fischer, B., Russell, C., Sabioni, P., van den Brink, W., Le Foll, B., Hall, W., Rehm, J., & Room, R. (2017) · American Journal of Public Health · doi:10.2105/ajph.2017.303818 · Cited by 433
Tait, R. J., Caldicott, D., Mountain, D., Hill, S. L., & Lenton, S. (2016) · Clinical Toxicology · doi:10.3109/15563650.2015.1110590 · Cited by 378
Murray, R. M., Quigley, H., Quattrone, D., Englund, A., & Di Forti, M. (2016) · World Psychiatry · doi:10.1002/wps.20341 · Cited by 315
Gone to Pot – A Review of the Association between Cannabis and Psychosis
Radhakrishnan, R., Wilkinson, S. T., & D’Souza, D. C. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00054 · Cited by 310
Spicing things up: synthetic cannabinoids
Spaderna, M., Addy, P. H., & D’Souza, D. C. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3188-4 · Cited by 296
The hallucinogenic world of tryptamines: an updated review
Araújo, A. M., Carvalho, F., Bastos, M. D. L., Guedes de Pinho, P., & Carvalho, M. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1513-x · Cited by 292
Gracia-Lor, E., Castiglioni, S., Bade, R., Been, F., Castrignanò, E., Covaci, A., González-Mariño, I., Hapeshi, E., Kasprzyk-Hordern, B., Kinyua, J., et al. (2017) · Environment International · doi:10.1016/j.envint.2016.12.016 · Cited by 289
Fantegrossi, W. E., Moran, J. H., Radominska-Pandya, A., & Prather, P. L. (2014) · Life Sciences · doi:10.1016/j.lfs.2013.09.017 · Cited by 261
Self-citationThe adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects
van Amsterdam, J., Brunt, T., & van den Brink, W. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565142 · Cited by 244
Novel halogenated derivates of JWH-018: behavioral and binding studies in mice
Vigolo, A., Ossato, A., Trapella, C., Vincenzi, F., Rimondo, C., Seri, C., Varani, K., Serpelloni, G., & Marti, M. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.02.008 · Cited by 91
Cannabinoid Hyperemesis Syndrome: A Review of Potential Mechanisms
DeVuono, M. V., & Parker, L. A. (2020) · Cannabis & Cannabinoid Research · doi:10.1089/can.2019.0059 · Cited by 87
Emergence and properties of spice and bath salts: a medicinal chemistry perspective
Lewin, A. H., Seltzman, H. H., Carroll, F. I., Mascarella, S. W., & Reddy, P. A. (2014) · Life Sciences · doi:10.1016/j.lfs.2013.09.026 · Cited by 72
“5-Hydroxypentyl metabolites are major players in the activity of SC (Grigoryev et al., 2013; Nakajima et al., 2012; Rajasekaran et al., 2013; Seely et al., 2012).”
BackgroundShifting drug markets in North America - a global crisis in the making?
Meyer, M., Westenberg, J. N., Jang, K. L., Choi, F., Schreiter, S., Mathew, N., King, C., Lang, U. E., Vogel, M., & Krausz, R. M. (2023) · International Journal of Mental Health Systems · doi:10.1186/s13033-023-00601-x · Cited by 41
“The use of these novel modified psychotropic substances has been associated with fatal outcomes and numerous, some-times life-threatening, side effects which are reported in literature [24–26].”
BackgroundActivity-based detection of synthetic cannabinoid receptor agonists in plant materials
Timmerman, A., Balcaen, M., Coopman, V., Degreef, M., Pottie, E., & Stove, C. P. (2024) · Harm Reduction Journal · doi:10.1186/s12954-024-01044-4 · Cited by 8
“However, this analytical method is costly and time-consuming, limiting its routine implementation for high-throughput screening and in resource-limited settings [14, 16–18].”
Method
Metadata
- Authors
- Seely, K. A., Lapoint, J., Moran, J. H., & Fattore, L.
- Venue
- Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2012-12
- Volume
- 39
- Issue
- 2
- Pages
- 234-243
- ISSN
- 0278-5846 (ISSN-L)
- OpenAlex
- W2110036909
- Cited by
- 465
- References
- 106
- FWCI
- 62.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.